Rockwell Medical

323 articles with Rockwell Medical

• Rockwell Medical, Inc. Files Pre-IND Meeting Request with FDA for its Proposed Clinical Trial of FPC as a Treatment for Iron Deficiency Anemia in Patients Receiving Home Infusion

  6/28/2021

  Rockwell Medical, Inc. announced that it has submitted a pre-IND meeting request with the U.S. Food and Drug Administration in support of its proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate, designed for the treatment of iron deficiency anemia and maintenance of hemoglobin in patients receiving infusion therapy in the home setting.

• Rockwell Medical Announces Extension of Multi-Year Distribution Agreement with Nipro Medical Corporation for Dialysis ConcentratesProvides for minimum of approximately $11.4M in purchases over 3-year Period

  6/11/2021

  Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it extended its distribution agreement with its long-term distribution partner, Nipro Medical Corporation (NMC), for a period of three years through May 2024.

• Rockwell Medical and Drogsan Pharmaceuticals Enter into Exclusive License Agreement for the Rights to Commercialize Triferic® in Turkey

  6/8/2021

  With approximately 65,000 patients receiving hemodialysis annually, Turkey represents a significant and expanding market opportunity

• Rockwell Medical, Inc. to Present at the 2021 LD Micro Invitational XI

  6/3/2021

  Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, announced that members of its executive management team will be presenting at the 2021 LD Micro Invitational XI on June 10th at 2:30pm EDT.

• Rockwell Medical, Inc. Provides First Quarter 2021 Financial and Operational Update

  5/17/2021

  Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, reported financial results and a business update for the three months ended March 31, 2021.

• Rockwell Medical, Inc. to Report First Quarter 2021 Financial and Operating Results on May 17, 2021

  5/3/2021

  Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, announced that it will host a conference call on Monday, May 17, 2021, at 4:30 p.m. ET to discuss its financial results for the three months ended March 31, 2021, and recent operational highlights.

• Rockwell Medical Announces Marketing Approval of Triferic® AVNU™ in Canada

  4/27/2021

  Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, announced that Triferic AVNU received a Notice of Compliance from Health Canada for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease.

• Rockwell Medical Presents Data on Diagnosis and Management of Iron Deficiency Anemia in Home Parenteral Nutrition Patients at the NHIA 2021 Annual Conference

  4/22/2021

  Rockwell Medical, Inc. (Nasdaq: RMTI), today announced that it presented data from a clinical feasibility study reviewing the practice patterns of iron deficiency anemia (IDA) in home parenteral nutrition patients at the National Home Infusion Association’s (NHIA) 2021 Annual Conference

• Rockwell Medical, Inc. Provides Fourth Quarter and Full Year 2020 Financial and Operational Update

  3/31/2021

  Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, reported financial results and a business update for the three months and full year ended December 31, 2020.

• Rockwell Medical, Inc. to Report Fourth Quarter and Full Year 2020 Financial and Operating Results on March 31, 2021

  3/18/2021

  Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it will host a conference call on Wednesday, March 31, 2021, at 4:30 p.m. ET to discuss its financial results for the three months and full year ended December 31, 2020,

• Rockwell Medical, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference

  3/4/2021

  Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that members of its executive management team are scheduled to present at the H.C. Wainwright Global Life Sciences Conference.

• Rockwell Medical Announces U.S. Availability of Triferic® AVNU for Replacement of Iron and Maintenance of Hemoglobin in Patients on Hemodialysis

  2/9/2021

  Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that Triferic AVNU (ferric pyrophosphate citrate injection), the intravenous (IV) formulation of Triferic, is now available to patients in the United States.

• Rockwell Medical Announces Submission of Triferic® New Drug Application in South Korea by Partner, Jeil Pharmaceutical Co., Ltd.>82,000 patients receiving hemodialysis annually

  2/1/2021

  Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and iron deficiency anemia management, today announced that its partner in South Korea, Jeil Pharmaceutical Co., Ltd., filed New Drug Applications (NDA) with the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea for Triferic AVNU and Triferic Dialysate

• Rockwell Medical, Inc. to Present at H.C. Wainwright BioConnect 2021 Conference

  1/5/2021

  Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and iron deficiency anemia management and improving outcomes for patients around the world, announced the Rockwell Medical executive management team will record a presentation at H.C. Wainwright BioConnect 2021 Conference.

• 

  BioSpace Movers & Shakers, Dec. 18

  12/18/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Industry Veteran Andrea Heslin Smiley joins Rockwell Medical’s Board of Directors

  12/16/2020

  Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and iron deficiency anemia management and improving outcomes for patients around the world, announced the appointment of industry leader and renowned life science industry executive, Ms. Andrea Heslin Smiley, to its Board of Directors, effective December 11, 2020.

• Rockwell Medical, Inc. Provides Third Quarter 2020 Financial and Operational Update

  11/9/2020

  Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and iron deficiency anemia management and improving outcomes for patients around the world, today reported financial results and a business update for the three months ended September 30, 2020.

• Rockwell Medical to Report Third Quarter 2020 Financial and Operating Results on November 9, 2020

  10/27/2020

  Rockwell Medical, Inc. (Nasdaq: RMTI) ("Rockwell Medical" or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and iron deficiency anemia management and improving outcomes for patients around the world, today announced that it will host a conference call on Monday, November 9, 2020, at 4:30 p.m.

• Rockwell Medical, Inc. Announces Presentations at the American Society of Nephrology Virtual Kidney Week 2020

  10/13/2020

  Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that two abstracts have been accepted for poster presentation at the American Society of Nephrology (ASN) Virtual Kidney Week 2020, which will occur from October 20 to 25, 2020.

• Rockwell Medical Announces Growth Plan and New Therapeutic Opportunities for Its Ferric Pyrophosphate Citrate (FPC) Platform

  9/24/2020

  Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and iron deficiency anemia management and improving outcomes for patients around the world, earlier today concluded its Management and Key Opinion Leader (KOL) conference call and webcast to discuss potential novel indications for its ferric pyrophosphate citrate (FPC) platform.